Clinical Guides
Intrauterine Contraception
A source-grounded clinical guide to copper and levonorgestrel intrauterine contraception, safe selection, insertion pathways and Indian programme context, prepared for specialist review.
MedNext Academy | 14 min read
Intrauterine Contraception
A source-grounded clinical guide to copper and levonorgestrel intrauterine contraception, safe selection, insertion pathways and Indian programme context, prepared for specialist review.
Summary
Intrauterine contraception comprises small devices placed in the uterine cavity by a trained provider. Copper-bearing IUDs release copper and are hormone-free; levonorgestrel-releasing IUDs release a progestogen locally. Both are highly effective, long-acting and reversible. WHO states that fewer than one pregnancy occurs per 100 users in the first year. Product-specific duration varies: copper devices may remain effective for approximately 10 to 12 years and levonorgestrel devices for about 3 to 8 years, but the exact approved duration must be checked for the actual product. Fertility returns promptly after removal.
Method choice should reflect the person’s reproductive goals, menstrual pattern, medical eligibility, uterine anatomy, infection risk, access and preference. Copper IUDs can increase bleeding and cramping, particularly initially, while levonorgestrel IUDs commonly cause irregular bleeding before often reducing menstrual loss or producing amenorrhoea. Neither method protects against HIV or other sexually transmitted infections, so condoms remain important when exposure risk exists. A copper IUD also provides the most effective emergency contraception when inserted within the appropriate window.
Safe care requires voluntary informed consent, reasonable exclusion of pregnancy, a focused history, pelvic assessment immediately before insertion, infection-prevention technique, competent fundal placement and clear follow-up instructions. Severe pain, fever, heavy bleeding, pregnancy symptoms, partial expulsion or suspected perforation require assessment. This guide is educational and cannot teach or certify the insertion skill; it remains quarantined pending specialist review.
How Common Is It?
IUDs are used globally across adolescence, nulliparity, postpartum life and later reproductive years, but uptake varies substantially by country, community, method availability and provider confidence. WHO describes both copper and levonorgestrel IUDs as among the most effective reversible contraceptives. Their effectiveness is not dependent on remembering a daily or per-coital action after correct placement, which is valuable for people who want highly reliable spacing without a permanent method. Continuation nevertheless depends on informed choice, tolerable bleeding patterns and easy access to review and removal.
Population percentages should be interpreted cautiously. Surveys may group copper and hormonal devices together, count only current users, omit private care or reflect older programme formularies. India’s 2018 government reference manual cited historical NFHS figures and programme uptake, but those figures do not describe the national position in 2026. This guide therefore makes no current Indian prevalence claim. It uses the manual for service structure and public-programme product context, while current WHO guidance controls clinical eligibility and effectiveness statements.
Need for intrauterine contraception is broader than measured uptake. Some people prefer a hormone-free option; others seek lighter menstrual bleeding; some need immediate postpartum or post-abortion contraception; and some want emergency contraception that continues long term. Barriers include myths about infertility, fear of insertion, partner influence, lack of trained providers, cost, geographical access and inability to obtain removal. A high-quality service measures informed, voluntary access and continuation, not merely insertion numbers.
Risk Factors
Risk assessment begins with pregnancy possibility and conditions that change method eligibility. Current pregnancy is a contraindication to insertion. Puerperal sepsis, current pelvic inflammatory disease, current purulent cervicitis or untreated gonorrhoea or chlamydia, unexplained vaginal bleeding requiring evaluation, genital malignancy and a uterine cavity distorted so that correct placement is impossible may preclude or delay insertion. Exact WHO medical eligibility categories differ for initiation versus continuation and for copper versus levonorgestrel devices; use the current table rather than a memorised generic list.
Copper and levonorgestrel devices have different clinical implications. Heavy or painful menstruation and iron-deficiency anaemia may become harder to tolerate with copper, although anaemia is not automatically an absolute contraindication. A levonorgestrel IUD may improve heavy bleeding but requires eligibility review in current or previous breast cancer and some severe liver conditions. Copper allergy or Wilson disease requires product-specific specialist advice. Prior ectopic pregnancy does not by itself prohibit an IUD: the overall pregnancy rate, including ectopic pregnancy, is very low, but any pregnancy with an IUD in place needs urgent location assessment.
Insertion-related risk rises with unrecognised pregnancy, active infection, difficult anatomy, inadequate training or poor asepsis. Postpartum insertion has timing-specific benefits and expulsion considerations. Perforation is uncommon but may be more likely in certain postpartum or breastfeeding contexts; follow current guidance and operator training. Nulliparity and adolescence are not automatic exclusions.
Also assess reproductive coercion, inability to return for removal, misconceptions and pressure from family or services. A technically eligible person may reasonably decline. Consent for an IUD is method-specific and revocable, and removal should be available when requested.
Diagnosis
There is no disease diagnosis required to choose an IUD. The assessment establishes contraceptive goals, medical eligibility, reasonable certainty that the person is not pregnant, pelvic suitability and whether symptoms require evaluation before insertion. Screening should be focused and should not create unnecessary barriers.
History
Ask about desired duration, future pregnancy plans, preference regarding hormones, menstrual bleeding and pain, last menstrual period, intercourse since the last period, current method and recent emergency contraception. Review pregnancy, birth, miscarriage or abortion timing; prior ectopic pregnancy; pelvic infection or STI exposure; abnormal discharge, fever, pelvic pain or dyspareunia; unexplained bleeding; cervical screening history; uterine anomalies, fibroids or surgery; breast or liver disease; anaemia; medicines; allergies; and previous IUD experience. Offer private screening for coercion and assess consent. A positive STI-risk history prompts appropriate testing or treatment but should be managed with current guidance rather than an indiscriminate exclusion rule.
Examination
Immediately before insertion, obtain consent, offer a chaperone, assess general stability when indicated, and perform abdominal and bimanual examination to identify tenderness, mass, uterine size and position. Speculum examination assesses the cervix and discharge. Findings suggesting active infection, pregnancy, unexplained bleeding or distorted anatomy require investigation or referral. Insertion is an aseptic procedure by a trained provider; sounding, loading and fundal placement are practical competencies, not skills learned safely from text alone.
Investigations
Use a validated pregnancy-exclusion checklist and pregnancy testing when uncertainty remains, recognising that a very early test can be negative. STI testing is risk-based and follows local protocols; results need not always delay insertion when the person is asymptomatic and same-day screening and treatment pathways exist, but current WHO and local policy must be applied. Full blood count is reasonable when heavy bleeding or anaemia is suspected. Ultrasound is not routine before uncomplicated insertion, but it is useful for uncertain uterine anatomy, a pelvic mass, difficult placement, missing threads, suspected perforation or pregnancy location.
Differential Diagnosis
Symptoms before insertion may indicate a condition needing treatment rather than a routine contraceptive visit. Amenorrhoea or delayed menses raises pregnancy, lactational amenorrhoea, endocrine disturbance or cycle variation. Pelvic pain with fever, discharge or cervical tenderness suggests pelvic inflammatory disease; pain with a positive pregnancy test raises ectopic pregnancy. Heavy or intermenstrual bleeding may reflect fibroids, adenomyosis, ovulatory dysfunction, cervical disease, pregnancy complications or malignancy and should not be attributed to contraception before insertion. A distorted cavity may result from submucosal fibroids or congenital anomaly.
After insertion, expected adaptation must be distinguished from complications. Copper commonly causes heavier or longer bleeding and more cramping in early months. Levonorgestrel IUDs commonly cause irregular spotting initially and may later produce light bleeding or amenorrhoea. New severe or persistent pain, fever, purulent discharge, heavy bleeding, dyspareunia, pregnancy symptoms, altered thread length or feeling plastic at the cervix requires assessment for infection, partial or complete expulsion, malposition, perforation or pregnancy.
Missing threads have several explanations: strings drawn into the cervical canal or uterus, unnoticed expulsion, pregnancy with expulsion, string breakage, malposition or perforation. Do not assume perforation or blindly instrument the uterus. Exclude pregnancy, examine, and locate the device with appropriate imaging and trained care.
If pregnancy occurs with an IUD in place, establish location and viability and assess sepsis risk. Ectopic pregnancy represents a greater proportion of these rare pregnancies even though IUD use reduces absolute ectopic risk by preventing pregnancy overall. Management depends on location, gestation, device position and the patient’s wishes.
Management
Begin with balanced counselling. Compare copper and levonorgestrel devices, expected duration for the available product, effectiveness, bleeding changes, insertion experience, expulsion, infection and perforation risks, lack of STI protection, emergency-contraception capability of copper, return of fertility and removal access. Discuss equally suitable alternatives. Consent must be voluntary and should be reconfirmed immediately before the procedure, including after antenatal counselling for postpartum placement.
An interval IUD can be inserted when pregnancy is reasonably excluded and current eligibility criteria are met; insertion need not be restricted mechanically to menstruation. A copper IUD used for emergency contraception should be placed within the current recommended window by an eligible trained provider. Immediate post-abortion insertion can be appropriate when abortion is complete and there is no sepsis, with eligibility differing after septic abortion. Postpartum placement may be post-placental, intra-caesarean or within the accepted immediate postpartum interval; timing outside that interval requires current guidance because expulsion and perforation considerations change.
Use aseptic non-touch technique and the product-specific insertion procedure. Do not provide prophylactic antibiotics routinely unless current local protocol identifies a specific indication. Record device type, lot where required, insertion date, expected replacement or review date, uterine sounding if locally required, any difficulty and the counselling given. Provide an IUD card or equivalent written record.
Manage troublesome bleeding, pain or absent bleeding after excluding pregnancy, infection, expulsion and pathology. Mild early symptoms may respond to reassurance and an appropriate analgesic after contraindication review. Persistent unacceptable effects justify method change or removal. Remove on request, at expiry, for pregnancy planning, certain complications or when medical eligibility changes; never make removal conditional on partner or family permission.
Prescribing Information
An IUD is a medical device rather than a conventional prescription, but safe provision requires product-level verification. Confirm whether the device is copper-bearing or levonorgestrel-releasing, its copper surface or hormone content, inserter, approved duration, storage, package integrity, expiry date and local registration. Do not apply WHO’s broad duration ranges to every product. In India’s 2018 public-programme manual, Cu 380A was listed for up to 10 years and Cu 375 for up to 5 years; current procurement and product labelling must be checked because programmes and products change.
Analgesia should be individualised. Explain likely cramping and offer an appropriate oral analgesic when safe; do not promise a painless procedure. Routine cervical priming is not required for every insertion and can cause adverse effects. Local anaesthesia, ultrasound guidance or specialist insertion may help selected patients, including those with prior difficult insertion, cervical stenosis or high anxiety. Verify medicine allergies, renal or gastrointestinal risks before recommending an NSAID.
Levonorgestrel exposure is predominantly local but not devoid of systemic effects. Irregular bleeding, headache, breast symptoms, acne or mood symptoms may occur; evidence and causality vary. Check current eligibility for breast cancer and severe liver disease. Copper avoids progestogen exposure but may worsen menstrual loss or dysmenorrhoea. Assess and treat iron deficiency when clinically indicated.
No IUD protects against STI. Condoms can be used concurrently. If pelvic infection is diagnosed after insertion, initiate appropriate antimicrobial treatment promptly; immediate routine removal is not always required, and the decision should follow current guidance, clinical response and patient preference. Never use this text as a substitute for product instructions, competency-based insertion training or an emergency protocol.
When to Refer
Refer to a trained or more experienced inserter when uterine position or size is uncertain, the cavity may be distorted, the cervix cannot be negotiated safely, previous insertion was difficult, threads or device location are uncertain, or ultrasound guidance may be needed. Stop rather than force an instrument if sounding is unexpectedly deep, resistance is abnormal, pain is severe or perforation is suspected. Postpartum, post-abortion and adolescent services should follow provider-competency and facility standards.
Arrange prompt gynaecology or imaging assessment for suspected perforation, embedded device, extrauterine device, partial expulsion that cannot be managed safely, pregnancy with an IUD, persistent severe pain, unexplained heavy bleeding, recurrent expulsion or a suspected uterine anomaly. A device seen outside the uterine cavity requires specialist removal planning; repeated blind retrieval attempts increase harm. Missing threads without pain may be evaluated non-emergently, but pregnancy risk and need for backup contraception must be addressed immediately.
Urgent referral is required for haemodynamic instability, peritonism, sepsis, severe abdominal or pelvic pain, a positive pregnancy test with pain or bleeding, or major haemorrhage. Evaluate ectopic pregnancy regardless of whether the device appears correctly placed. If pregnancy is intrauterine and continuing, specialist counselling should cover miscarriage, infection and preterm risks, and whether accessible threads permit removal.
Referral is also appropriate when complex medical eligibility is uncertain, such as active malignancy, major liver disease, severe unexplained anaemia or interactions with ongoing treatment plans. A good referral documents device and insertion details, last menstrual period, pregnancy testing, symptoms, examination, infection testing or treatment, thread findings, imaging and the patient’s preference about continuation or removal.
Red Flags
After insertion, urgent assessment is required for severe or worsening lower abdominal pain, fever, rigors, foul or purulent discharge, very heavy bleeding, collapse, syncope, shoulder-tip pain, a positive pregnancy test, or symptoms of peritonism. These findings may indicate infection, perforation, ectopic pregnancy, miscarriage or another acute pelvic condition. Mild cramping and spotting can be expected, but expected effects should improve and must not be used to dismiss physiological deterioration.
Possible expulsion is signalled by seeing the device, feeling hard plastic at the cervix or vagina, a major change in thread length, new cramping or bleeding, or inability to feel previously palpable threads. Thread self-checking should never be compulsory and technique advice varies. Until device position and pregnancy risk are assessed, use condoms or abstain and consider whether emergency contraception is needed for recent intercourse. Do not push a partially expelled device back into the uterus.
Pregnancy with an IUD is uncommon but high stakes. Pain, bleeding, dizziness or shoulder-tip pain requires an ectopic pathway. Fever, uterine tenderness or offensive discharge in a pregnant person with an IUD raises septic miscarriage risk. A positive test without symptoms still requires timely clinical review to establish location and discuss options.
During insertion, severe disproportionate pain, vasovagal collapse that does not resolve, unexpected loss of resistance, excessive sounding depth or significant bleeding should stop the procedure and trigger assessment. Respect psychological red flags too: withdrawal of consent, panic, trauma response or coercion requires pausing or stopping. A contraceptive goal never justifies completing a procedure against the person’s current wishes.
Indian Clinical Context
The Ministry of Health and Family Welfare’s March 2018 Reference Manual for IUCD Services describes copper devices within India’s public Family Planning Programme, specifically Cu 380A and Cu 375, and covers interval, postpartum and post-abortion services. It is a valuable operational source for counselling, client assessment, infection prevention, provider training, records and referral. It does not establish that every facility stocks both devices in 2026, and it does not cover the full current private-sector range of levonorgestrel IUDs. Verify local stock, approved duration and provider competence.
The manual’s postpartum pathway includes post-placental placement, intra-caesarean placement and insertion within 48 hours, with later insertion deferred to the interval specified in the applicable protocol. Current WHO eligibility guidance must be reconciled with local obstetric policy, especially after puerperal sepsis, prolonged rupture of membranes or complicated delivery. Antenatal counselling is valuable, but consent should be reconfirmed when the patient is comfortable and able to choose; labour pain or surgical admission must not be exploited to secure acceptance.
Access differs across subcentres, primary health centres, district hospitals and private facilities. A referral offer is meaningful only if travel, cost and removal access are explained. ASHA or ANM counselling can support informed choice, but targets or incentives must never override voluntariness. Nulliparity, youth or marital status should not be treated as automatic biological contraindications.
Indian users may encounter the term IUCD or Copper-T more often than IUD. Explain the actual device rather than relying on a nickname. Do not assert a current national uptake rate from the 2018 manual. Use a current method eligibility chart, product label, infection-control standard and facility escalation pathway at every insertion service.
NMC Competency Mapping
NMC CBME Curriculum 2024 maps intrauterine contraception to two competencies. OG21.1 requires description and discussion of temporary and permanent contraception, including indications, technique, complications, patient selection, side effects and failure rate, and explicitly includes IUCDs. OG21.2 requires learners to enumerate indications, describe the steps, and insert and remove an intrauterine device in a simulated environment. The second competency is a practical skill outcome; reading this guide does not certify it.
At Know and Know How level, learners should compare copper and levonorgestrel IUDs, explain mechanisms and product-specific duration, apply WHO eligibility categories, reasonably exclude pregnancy, recognise infection or cavity concerns, and counsel about bleeding, effectiveness, STI protection and fertility return. They should distinguish interval, emergency, postpartum and post-abortion pathways and understand why timing and sepsis alter eligibility.
At Show How level, students can demonstrate counselling and consent, equipment preparation, infection prevention, bimanual and speculum assessment, safe insertion and removal steps on a validated simulator, documentation, post-procedure advice and recognition of a difficult or unsafe procedure. Clinical performance requires supervised training, local credentialling and enough experience to stop and refer appropriately.
Integration covers reproductive anatomy and physiology, microbiology, pharmacology of levonorgestrel, menstrual disorders, postpartum care, ethics, communication and public health. Assessment should include voluntary choice and removal access, not just mechanical insertion. Formal teaching should use the institution’s current logbook and NMC ledger, preserving OG21.1 and OG21.2 as the explicit anchors.
Key Exam Pearls for NEET PG
IUDs are long-acting reversible contraception with fewer than one pregnancy per 100 users in the first year. Copper produces a local spermicidal environment and prevents fertilisation; levonorgestrel thickens cervical mucus, suppresses the endometrium and may inhibit sperm function. Fertility returns promptly after removal. Copper devices may increase bleeding and dysmenorrhoea, while levonorgestrel devices usually reduce bleeding after an initial irregular phase. Neither prevents STI.
A copper IUD is the most effective emergency contraceptive when inserted within 120 hours and can remain for ongoing contraception. Duration is product-specific: WHO gives approximate ranges of 10 to 12 years for copper and 3 to 8 years for hormonal devices. India’s 2018 programme manual lists Cu 380A for 10 years and Cu 375 for 5 years; never generalise one product’s duration to another.
Before insertion, exclude pregnancy reasonably, take an infection and bleeding history, assess uterine size and position, inspect the cervix and use aseptic technique. Current pregnancy, puerperal sepsis, current PID or purulent cervicitis, unexplained bleeding needing evaluation and a distorted cavity are key reasons to defer or avoid insertion, but categories are method- and situation-specific. Nulliparity is not an automatic contraindication.
Post-insertion differentials are expected bleeding, infection, expulsion, malposition, perforation and pregnancy. Missing threads do not prove perforation: exclude pregnancy and locate the device. Pregnancy with an IUD requires ectopic exclusion. Severe pain, fever, heavy bleeding or collapse is urgent. OG21.2 tests simulated insertion and removal skill, not merely recall of device facts.
Frequently Asked Questions
Can someone who has never given birth use an IUD?
Yes. Nulliparity is not an automatic contraindication to copper or levonorgestrel intrauterine contraception. Eligibility depends on pregnancy exclusion, infection and STI assessment, uterine anatomy, bleeding symptoms, medical conditions and informed preference. Insertion may be more uncomfortable or technically difficult in some patients, so competent technique, analgesia discussion and access to specialist insertion matter.
Do intrauterine devices cause permanent infertility after removal?
No. WHO states that fertility returns immediately after IUD removal. An IUD itself does not create permanent infertility. Untreated sexually transmitted infection can damage fertility, which is why risk assessment, testing or treatment when indicated, condom counselling and prompt review of pelvic infection symptoms are important. Removal should be available whenever the user requests it.
What should happen when IUD threads cannot be felt?
Use condoms or abstain until pregnancy risk and device position are assessed, and consider emergency contraception if recent intercourse was unprotected. A clinician should exclude pregnancy, examine for retracted threads or partial expulsion, and arrange ultrasound or other imaging when needed. Missing threads may reflect retraction, expulsion, breakage, malposition or perforation; blind repeated instrumentation is unsafe.
Which bleeding changes are expected with an intrauterine device?
Copper devices may cause heavier, longer or more painful periods, especially during early months. Levonorgestrel devices commonly cause irregular spotting at first, followed by lighter bleeding or amenorrhoea in some users. Very heavy bleeding, severe pain, fever, pregnancy symptoms or a new pattern after stability needs assessment for anaemia, infection, expulsion, pregnancy or unrelated pathology.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic